Evercore analyst Elizabeth Anderson CFA maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and maintains the target price at $235.
According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of -8.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
The company indicates that the market remains relatively stable, although challenges in bookings arise from delays and drug failures rather than a significant impact from pipeline rationalization.
The company has encountered a difficult industry operating climate. Despite this, indications show that pharmaceutical portfolio reprioritizations related to the IRA may be concluding, and the company seems to be gaining from pharmaceutical companies' vendor consolidation trends.
Iqvia's recent financial performance saw total revenue, adjusted EBITDA, and adjusted EPS surpass consensus expectations. Nevertheless, the company has reduced its 2024 outlook on all metrics, attributing the adjustment to the Inflation Reduction Act and broader economic challenges. Contributing factors to the revised guidance include delays and cancellation of two significant trials, as reported by an analyst.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Evercore分析師Elizabeth Anderson CFA維持$艾昆緯 (IQV.US)$買入評級，維持目標價235美元。
根據TipRanks數據顯示，該分析師近一年總勝率為36.8%，總平均回報率為-8.3%。
此外，綜合報道，$艾昆緯 (IQV.US)$近期主要分析師觀點如下：
公司表示，儘管面臨來自延誤和藥品失效而非來自管道優化的預訂挑戰，但市場仍然相對穩定。
公司遭遇了艱難的行業經營氛圍。儘管如此，跡象顯示，與IRA相關的藥品組合重排可能即將結束，並且公司似乎正在從藥品公司的供應商整合趨勢中獲益。
Iqvia近期的財務表現超過了共識預期，總收入、調整後EBITDA和調整後每股收益均超過了共識預期。然而，公司已經下調了對所有指標的2024年展望，將調整歸因於通脹降低法令和更廣泛的經濟挑戰。修訂指引的貢獻因素包括兩項重要試驗的延遲和取消，據一位分析師報告。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
